Join Now - it is FREE

Basic level includes our interactive biotech chatroom, forum, biotech stock screener; you also receive the biotech digest in your email everyday.

Eiger BioPharmaceuticals ($EIGR) announced the completion of enrollment for its Phase 2 multiple-ascending dose study assessing subcutaneous exendin 9-39 for the treatment of post-bariatric surgery patients who are experiencing dangerously low postprandial blood glucose levels. The company intends to present the data on June 11th at the American Diabetes Association meeting in San Diego. Exendin 9-39 is a peptide the selectively targets and blocks GLP-1 receptors which normalizes insulin secretion by the pancreas and reduces PBH.

The company stock has shown rather weak performance in the recent past. It lost 41 percent of its value this year so far while its 12 months loss stands at 70 percent.

<p align="left">

</p>

Viking Therapeutics Inc. ($VKTX) announced that it has received encouraging preclinical results for NASH candidate VK2809. The stock reacted positively to the news and closed 5 percent higher. In a mouse model of diet-induced NASH, treatment with orally available VK2809 for eight weeks resulted in statistically significant improvements in non-alcoholic fatty liver disease activity score. It also showed statistically significant improvements for liver collagen content and liver fibrosis compared to controls.

VK2809 is an orally available, tissue and receptor-subtype selective agonist of the thyroid beta receptor. Viking Therapeutics is a clinical-stage biopharmaceutical company focused on the development of novel therapies for metabolic and endocrine disorders

<p align="left"><span style="line-height: 1.5;">

</span></p>
&nbsp;

Intellipharmaceutics International ($IPCI) announced the initiation of the  U.S. commercial launch of its generic version of AstraZeneca's antidepressant Seroquel XR for treating schizophrenia and bipolar disorder. The company is collaborating with Mallinckrodt for the distribution of the treatment.

Aldeyra Therapeutics ($ALDX) announced that it has enrolled its first patient for Phase 2a clinical trial assessing topical ocular ADX-102, for the treatment of dry eye disease. The primary endpoint is safety and tolerability through day 29.

Novo Nordisk ($NVO) announced receiving the European Commission’s approval for its Refixia for the treatment of adolescents and adults with hemophilia B. The commercial launch of the product will start in the fourth quarter.

CEL-SCI Corporation ($CVM) announced that it has responded to the FDA's most recent communication about the clinical hold imposed on the Company’s Phase 3 head and neck cancer study with Multikine. The FDA had noted that the study’s Investigator Brochure (IB) and the “Dear Investigator” letter need to be revised. 

<p align="left">

&nbsp;

Novanta ($NOVT) announced that it has signed a deal to acquire World of Medicine GmbH for 115 million euro in cash. The deal is expected to be closed in the next quarter. The company intends to use its credit facility for the purpose of financing the deal.

Innovus Pharmaceuticals ($INNV) announced the in-licensing of  thymol and carvacrol for the treatment of cachexia and muscle growth and repair from the University of Iowa Research Foundation. The company did not disclose the financial terms of the deal.

</p>

Brokerage

Action

Company

Rating

Price Target

Impact on Share Price

Cantor Fitzgerald

Reiterates

Abeona Therapeutics (ABEO)

Buy

$21.00

Medium

Cowen and Company

Reiterates

Adaptimmune Therapeutics PLC - (ADAP)

Buy

Low

Mizuho

Reiterates

Adamas Pharmaceuticals (ADMS)

Buy

$26.00

Low

HC Wainwright

Reiterates

Akebia Therapeutics (AKBA)

Buy

$25.00

Low

Canaccord Genuity

Downgrades

Alere (ALR)

Buy -> Hold

Medium

William Blair

Downgrades

Albany Molecular Research (AMRI)

Outperform -> Market Perform

Low

BMO Capital Markets

Reiterates

bluebird bio (BLUE)

Buy

$108.00

High

<p align="left">

</span></p>

Gainers (% price change) Last Trade Change Mkt Cap
Albany Molecular Research AMRI 21.53 +1.76 (8.90%) 905.99M
Oclaro, Inc. OCLR 10.48 +0.84 (8.71%) 1.82B
Zogenix, Inc. ZGNX 14.55 +0.93 (6.79%) 363.04M
II-VI, Inc. IIVI 32.75 +1.60 (5.14%) 2.06B
Synergy Pharmaceuticals SGYP 3.97 +0.18 (4.75%) 846.17M
Losers (% price change)
Celldex Therapeutics, Inc CLDX 2.39 -0.34 (-12.45%) 282.45M
CyberOptics Corporation CYBE 22.90 -1.30 (-5.37%) 163.39M
ImmunoGen, Inc. IMGN 4.78 -0.27 (-5.35%) 433.09M
Concord Medical Services CCM 3.45 -0.17 (-4.70%) 148.89M
Compugen Ltd. (USA) CGEN 4.15 -0.20 (-4.60%) 204.57M
Most Actives (dollar volume)
Johnson & Johnson JNJ 130.83 +0.46 (0.35%) 353.19B
Alere Inc ALR 49.97 +1.22 (2.50%) 4.33B
UnitedHealth Group Inc UNH 180.82 +1.45 (0.81%) 174.23B
Bristol-Myers Squibb Co BMY 51.66 -0.70 (-1.34%) 81.07B
Pfizer Inc. PFE 32.07 -0.28 (-0.87%) 189.87B

<p align="left">

</p>